greeksoup/ stocks
Stocks / United States / VRTX / Holders

Vertex Pharmaceuticals Inc. / MA 13F holders

Of the 44 funds followed here, 11 reported a position in Vertex Pharmaceuticals Inc. / MA in a 13F for the quarter ended 30 June 2026. The largest: Capital Research Global Investors, 19.5 million shares worth $9.68 billion, 1.4% of its reported book.

FundSharesValueOf its bookChange on the quarterStatusQuarter endedFiling
Capital Research Global Investors19,490,637$9.68 billion1.4%-1,635,327trimmed30 June 202613F
Geode Capital Management6,017,848$2.98 billion0.2%-121,773trimmed30 June 202613F
Norges Bank2,971,681$1.48 billion0.1%held30 June 202613F
FMR LLC1,457,158$723.8 million0.0%-563,107trimmed30 June 202613F
Citadel Advisors889,630$441.9 million0.1%+258,132added30 June 202613F
Millennium Management563,810$280.1 million0.1%+381,487added30 June 202613F
Renaissance Technologies320,008$159.0 million0.2%-101,680trimmed30 June 202613F
Two Sigma Investments287,400$142.8 million0.1%-91,746trimmed30 June 202613F
Baillie Gifford272,561$135.4 million0.1%+73,140added30 June 202613F
Point72 Asset Management18,625$9.3 million0.0%-1,575trimmed30 June 202613F
Bridgewater Associates10,865$5.4 million0.0%-2,492trimmed30 June 202613F

Value is what the fund reported. Change is shares against the fund's previous 13F; a fund with one filing read shows no change. 13Fs cover long US positions of managers above $100 million and are filed up to 45 days after the quarter.

Schedule 13D and 13G filed on the name, last twelve months

FiledScheduleWhoHoldingOf the classEvent dateRule or purposeFiling
14 May 202613G/ACapital World Investors and 1 other25.7 million10.1%31 March 2026passive, institutional (13d-1(b))EDGAR
14 May 202613G/ACapital Research Global Investors and 1 other21.1 million8.3%31 March 2026passive, institutional (13d-1(b))EDGAR
30 April 202613GVanguard Capital Management and 1 other19.0 million7.5%31 March 2026passive, institutional (13d-1(b))EDGAR
27 March 202613G/AThe Vanguard Group and 1 other00.0%13 March 2026passive, institutional (13d-1(b))EDGAR
12 February 202613G/ACapital Research Global Investors and 1 other17.3 million6.8%31 December 2025passive, institutional (13d-1(b))EDGAR

A Schedule 13D is filed by anyone who crosses 5% of a class with intent to influence; a 13G by a passive holder. Amendments (/A) report a change, including an exit to zero. Holding and percentage are as the filer stated them on the cover page; the purpose is the filer's own words, cut short.

Fails to deliver

Settlement dateShares failedPriceFile
31 August 20263$541.69SEC
26 August 20261,828$552.85SEC
25 August 20264,566$547.59SEC
24 August 2026237$548.05SEC
5 August 2026255$478.71SEC
28 July 2026608$479.00SEC
22 July 20263,256$482.00SEC
17 July 2026102$486.03SEC
16 July 202618$477.08SEC

Shares that failed to deliver at settlement, per day, from the SEC's half-month files, which arrive about two weeks after the period. Largest in the window: 4,566 on 25 August 2026. A fail is an operational fact about settlement, not a position.

Source

Each fund's 13F-HR on EDGAR, linked per row; positions matched to VRTX by CUSIP from the SEC's own fails-to-deliver files; Schedule 13D and 13G from the company's own filing index, each read to confirm the company is the issuer named.

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install